Nanexa AB (NANEXA) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.040x

Based on the latest financial reports, Nanexa AB (NANEXA) has a cash flow conversion efficiency ratio of -0.040x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.14 Million ≈ $-553.15K USD) by net assets (Skr127.13 Million ≈ $13.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nanexa AB balance sheet independence to measure how much of total assets are equity-financed.

Nanexa AB - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Nanexa AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Nanexa AB cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Nanexa AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nanexa AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Alcadon Group AB ST:ALCA	0.063x
OSE Pharma SA PA:OSE	-0.355x
Geodrill Limited TO:GEO	-0.009x
Coloray International Investment Co. Ltd KQ:900310	0.003x
HyVision System. Inc KQ:126700	-0.033x
Daehan Synthet KO:003830	-0.005x
Hektar Real Estate Investment Trust KLSE:5121	0.029x
Artiva Biotherapeutics, Inc. Common Stock NASDAQ:ARTV	-0.149x

Annual Cash Flow Conversion Efficiency for Nanexa AB (2014–2025)

The table below shows the annual cash flow conversion efficiency of Nanexa AB from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Nanexa AB stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr101.53 Million ≈ $10.93 Million	Skr-1.46 Million ≈ $-157.33K	-0.014x	+96.14%
2024-12-31	Skr70.92 Million ≈ $7.63 Million	Skr-26.43 Million ≈ $-2.84 Million	-0.373x	+16.29%
2023-12-31	Skr95.83 Million ≈ $10.31 Million	Skr-42.66 Million ≈ $-4.59 Million	-0.445x	-516.99%
2022-12-31	Skr109.10 Million ≈ $11.74 Million	Skr-7.87 Million ≈ $-847.05K	-0.072x	+56.56%
2021-12-31	Skr151.29 Million ≈ $16.28 Million	Skr-25.13 Million ≈ $-2.70 Million	-0.166x	+57.21%
2020-12-31	Skr43.35 Million ≈ $4.67 Million	Skr-16.83 Million ≈ $-1.81 Million	-0.388x	-2.54%
2019-12-31	Skr24.88 Million ≈ $2.68 Million	Skr-9.42 Million ≈ $-1.01 Million	-0.379x	+8.75%
2018-12-31	Skr16.29 Million ≈ $1.75 Million	Skr-6.76 Million ≈ $-727.11K	-0.415x	-124.54%
2017-12-31	Skr27.46 Million ≈ $2.95 Million	Skr-5.07 Million ≈ $-545.87K	-0.185x	+51.07%
2016-12-31	Skr16.96 Million ≈ $1.83 Million	Skr-6.41 Million ≈ $-689.32K	-0.378x	+30.46%
2015-12-31	Skr6.07 Million ≈ $652.70K	Skr-3.29 Million ≈ $-354.41K	-0.543x	-241.43%
2014-12-31	Skr1.47 Million ≈ $158.09K	Skr563.99K ≈ $60.69K	0.384x	--

About Nanexa AB

ST:NANEXA Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$82.83 Million

Skr769.64 Million SEK

Market Cap Rank

#19821 Global

#351 in Sweden

Share Price

Skr4.17

Change (1 day)

-2.80%

52-Week Range

Skr1.61 - Skr4.92

All Time High

Skr15.20